Change in Preferred Drug List Status for Antihyperuricemics Drug Class Takes Effect April 22, 2024

The manufacturer of brand name Colcrys products, Takeda Pharmaceuticals, confirmed these products were discontinued on Dec. 31, 2023, and some supplies of the products will remain available until exhausted from the market. In response, Medicaid will remove the non-preferred status from brand name Mitigare products on the preferred drug list (PDL).

HHSC removed the non-preferred status for the drugs below as of April 22, 2024. The preferred status of brand name Colcrys products will not change. This will allow existing stock of these medications to be used. These changes will allow providers to prescribe the brand name Mitigare products without requiring a PDL prior authorization and continue accessing necessary medication for clients.